SCHEMBL1023334

SCHEMBL1023334

N#CC(Cl)c1ccccc1F

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.40
TDO2 P48775 2/20 0.40
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CCR1 P32246 1/20 0.36
CNR2 P34972 2/20 0.35
ALDH1A1 P00352 5/20 0.35
GAA P10253 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GFER P55789 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAPT P10636 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
EEF2K O00418 1/20 0.32
TRPA1 O75762 1/20 0.31
TSHR P16473 1/20 0.31
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145600 1.00 IDO1 (0.40) IDO1TDO2CES2CES1CCR1
SCHEMBL11566406 0.76 ALDH1A1 (0.35) IDO1TDO2CES2CES1CCR1
SCHEMBL1629226 0.76 ALDH1A1 (0.47) IDO1TDO2CCR1ALDH1A1TDP1
SCHEMBL4910575 0.76 IDO1 (0.37) IDO1TDO2CES2CES1CCR1
SCHEMBL10907202 0.74 PARP10 (0.39) MAPT
SCHEMBL3495437 0.74 TSHR (0.50) IDO1TDO2CES2CES1CCR1
SCHEMBL2339911 0.74 ALDH1A1 (0.38) IDO1TDO2CES2CES1ALDH1A1
SCHEMBL7868609 0.74 IDO1 (0.40) IDO1TDO2CES2CES1CCR1
SCHEMBL27782003 0.74 TRPA1 (0.50) IDO1TDO2CES2CES1CCR1
SCHEMBL2163400 0.74 TSHR (0.50) IDO1TDO2CES2CES1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111253404-B Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2023-05-23 CN disclosed
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-02-17 US disclosed
EP-3889156-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2021-10-06 EP disclosed
CN-106795117-A Heterobicyclic compounds and their use for the treatment of tuberculosis 大塚制药株式会社 2017-05-31 CN disclosed
CN-102159207-B Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2015-02-04 CN disclosed
US-20140288074-A1 FUNGICIDAL PYRAZOLES E I DU PONT DE NEMOURS AND COMPANY (US) 2014-09-25 US disclosed
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
EP-0540143-A2 Compounds and methods for inhibition of HIV and related viruses Medivir Aktiebolag (SE) 1993-05-05 EP disclosed
EP-0382588-B1 METHOD FOR THE REDUCTION OF A REFINING CATALYST BEFORE ITS USE EURECAT EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) 1993-03-24 EP disclosed
WO-1993003022-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1993-02-18 WO disclosed
EP-0251775-B1 ALPHA-ARYL-ALPHA-PHENYLETHYL-1H-1,2,4-TRIAZOLE-1-PROPANENITRILES ROHM AND HAAS COMPANY (US) 1993-01-20 EP disclosed
EP-0349358-B1 PROCESS FOR PRESULFIDING AND CONTROLLING THE ACTIVITY OF A HYDROCARBON TREATMENT CATALYST EURECAT EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) 1992-03-04 EP disclosed
US-5087635-A Funcicides ROHM AND HAAS COMPANY (US) 1992-02-11 US disclosed
US-5059731-A Selectively hydrogenating acetylenic and diolefinic hydrocarbons EUROPEANE DE RETRAITEMENT DE CATALYSEURS EURECAT (FR) 1991-10-22 US disclosed
US-4983559-A CATALYTIC REGENERATION EUROPEENE DE RETRAITEMENT DE CATALYSEURS EURECAT (FR) 1991-01-08 US disclosed
EP-0349358-A1 Process for presulfiding and controlling the activity of a hydrocarbon treatment catalyst EURECAT EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) 1990-01-03 EP disclosed
EP-0251775-A2 Alpha-aryl-alpha-phenylethyl-1H-1,2,4-triazole-1-propanenitriles ROHM AND HAAS COMPANY (US) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 IDO1 1637/4885TDO2 1902/4885CES2 3923/4885
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof MAPK11, WEE1, NOS1 IDO1 1135/4885TDO2 2337/4885CES2 4408/4885
US-20140288074-A1 FUNGICIDAL PYRAZOLES CYP1A1, CYP1B1, NOX3 IDO1 181/4885TDO2 317/4885CES2 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.